Tirzepatid 30mg

▎ Kūlana Tirzepatid

▎ ʻImi ʻo Tirzepatid

He aha ke kumu noiʻi o Tirzepatid?

ʻO ke kumu o ka noiʻi ʻana o Tirzepatid ma muli o ka ʻimi ʻana i nā lāʻau lapaʻau maʻi diabetes a me ke koi no nā lāʻau hoʻokele kaumaha. He mau palena nā lāʻau lapaʻau kuʻuna maʻi diabetes, ʻoiai ʻo GLP-1 receptor agonists e hōʻike ana i ka pono nui i ka hoʻomaikaʻi ʻana i ke kahe koko koko, e koi ana i nā mea noiʻi e hoʻomohala i nā lāʻau lapaʻau ʻoi aku ka maikaʻi o ka papa like. Ma ke ʻano he GIP/GLP-1 ʻelua receptor agonist, hiki iā Tirzepatid ke hoʻoponopono maikaʻi i nā pae glucose koko. ʻO ka piʻi ʻana o ke ao holoʻokoʻa i ka nui o ka nui a me ka nui o ka heluna kanaka i hana i ka mālama paona i mea e koi koke ai. Loaʻa i ka GLP-1 receptor agonists nā hopena hoʻohaʻahaʻa kaumaha, e hoʻolilo iā lākou i pahuhopu no ka pohō kaumaha. Ua loaʻa ka manaʻo o Tirzepatid ma muli o kāna mau hopena maikaʻi i ke kaumaha.

He aha ke ʻano o ka hana a Tirzepatid?

ʻO ka hana agonist receptor pālua: 

ʻO Tirzepatid kahi ʻelua glucagon-like peptide-1 (GLP-1) a me ka glucose-dependent insulinotropic polypeptide (GIP) receptor agonist [1,2] (Wong E, 2023; Kumar D, 2022). ʻO GLP-1 a me GIP nā hormones incretin i hana ʻia i loko o ka ʻōpū, e pāʻani ana i kahi kuleana koʻikoʻi i ka mālama ʻana i ka homeostasis glucose. Hoʻohana ʻo Tirzepatid i kahi hopena synergistic ma ka hoʻoulu ʻana i ka GLP-1 a me GIP receptors, a laila e hoʻoponopono i nā pae glucose koko.

Hoʻoponopono i ka insulin a me ka huna ʻana o ka glucagon: 

Hoʻonui ia i ka synthesis a me ka huna ʻana o ka insulin i ka wā e hōʻemi ana i ka hoʻokuʻu ʻana o ka glucagon ma ke ʻano pili glucose. Ke piʻi ke kiʻekiʻe o ka glucose i ke koko, hoʻoulu ʻo Tirzepatid i nā pancreatic β-cells e hūnā i ka insulin, e hoʻoikaika ana i ka lawe ʻana a me ka hoʻohana ʻana i ka glucose, a laila e hoʻohaʻahaʻa i nā pae glucose koko; I ka manawa like, ke kāohi nei ia i nā pancreatic α-cells mai ka huna ʻana i ka glucagon, e hōʻemi ana i ka hoʻopuka ʻana o ka glucose hepatic, e hoʻohaʻahaʻa hou i ke kiʻekiʻe o ka glucose koko, a me ka hoʻomalu pono ʻana i ka hoʻokē ʻai a me ka postprandial blood glucose pae ^[1,3].

Nā ʻano hana ʻē aʻe: 

Hoʻoikaika pū ʻo Tirzepatid i ka satiety, e pili ana paha i ka hoʻoulu ʻana i nā mea hoʻokipa GLP-1, e hana ana i ka ʻōnaehana o ke kikowaena, a me ka hoʻoulu ʻana i nā kikowaena hoʻoponopono makemake, e alakaʻi ana i nā mea maʻi e hōʻemi i ka ʻai ʻana i ka meaʻai a ma laila e kōkua ai i ka pohō kaumaha. Hoʻopaneʻe hoʻi ia i ka hoʻokuʻu ʻana o ka ʻōpū, hoʻolōʻihi i ka manawa e waiho ai ka meaʻai i loko o ka ʻōpū a komo mālie i loko o ka ʻōpū liʻiliʻi, a laila e pale ai i ka piʻi wikiwiki ʻana o ke kiʻekiʻe o ka glucose koko ^[1].

Kiʻi 1 Mechanism o ka hana o T irzepatide ^[6].

He aha nā mea hoʻohana o T irzepatide?

Ka mālama ʻana i ka maʻi diabetes type 2: 

Ua ʻae ʻia ʻo Tirzepatid no ka mālama ʻana i nā poʻe maʻi me ka maʻi diabetes type 2 ma ke ʻano he mea hoʻohui i ka meaʻai a me ka hoʻoikaika kino. Ua hōʻike ʻia ka hoʻāʻo SURPASS ua hoʻemi nui ʻo Tirzepatid i ka pae hemoglobin A1c (HbA1c), me ka hoʻemi ʻana mai -1.87% a -2.59% (-20 a -28 mmol/mol). Hōʻike pū ia i ka mana glycemic kiʻekiʻe i hoʻohālikelike ʻia i kekahi mau agonists receptor GLP-1, e like me semaglutide 1 mg i ka hoʻāʻo SUPRASS-2. Eia hou, hiki iā ia ke hoʻemi i ke kaumaha o ke kino, me ka pohō kaumaha mai -6.2 a -12.9 kg i nā haʻawina hauʻoli, he mea koʻikoʻi loa ia no nā poʻe maʻi me ka maʻi maʻi type 2 i loaʻa pinepine i nā pilikia kaumaha a i ʻole ka momona ^[1,4].

Ka mālama ʻana i ka momona: 

No ka mea, hoʻolaha ʻo Tirzepatid i ka māʻona, hoʻemi i ka ʻai ʻana i ka meaʻai, a hoʻoikaika i ka pohō kaumaha, loaʻa iā ia ka waiwai therapeutic no nā maʻi me ka momona. Hōʻike nā haʻawina e hiki ke hoʻemi i ke kaumaha ma luna o 20%, hoʻomaikaʻi i ke kūlana metabolic o ka poʻe maʻi, a lawelawe ma ke ʻano he koho lapaʻau hou no ka momona, kōkua i nā poʻe maʻi obese e lilo i ka kaumaha a hoʻemi i ka pilikia o nā maʻi like ʻole e pili ana i ka momona ^[1,2].

Hoʻemi ʻia ka pilikia o ka maʻi cardiovascular: 

ʻO ka poʻe maʻi me ka maʻi diabetes type 2 e kū pinepine ana i ka piʻi nui o ka maʻi cardiovascular. Ma waho aʻe o ka hoʻohaʻahaʻa ʻana i ke kō koko a me ke kaumaha, ʻo Tirzepatid ka hopena maikaʻi i nā hōʻailona pili i ka cardiovascular, me ka hoʻohaʻahaʻa ʻana i ke koko, hoʻemi i ka hōʻiliʻili momona visceral, a me ka hoʻohaʻahaʻa ʻana i nā pae triglyceride, no laila e kōkua ai i ka hōʻemi ʻana i ka maʻi o ka maʻi cardiovascular a hoʻomaikaʻi i nā hopena cardiovascular ^[4].

Hiki ke mālama ʻia no ka steatohepatitis non-alcoholic (NASH): 

Loaʻa iā Tirzepatid nā hopena therapeutic kūpono ma NASH. Ma ka hoʻomaikaʻi ʻana i ka naʻau o ka insulin a me ka hoʻoponopono ʻana i ka glucose a me ka metabolism lipid, hiki iā ia ke hōʻemi i ka steatosis hepatic a me ka mumū, e hāʻawi ana i kahi kuhikuhi hou no ka mālama NASH ^[5].

Ka hopena

Ma ke ʻano he GIP/GLP-1 ʻelua receptor agonist, ua hōʻike ʻo Tirzepatid i ka hana koʻikoʻi i ka mālama ʻana i ka maʻi diabetes a me nā maʻi metabolic. Ma ka hoʻoponopono ʻana i ka huna ʻana o ka insulin a me ka glucagon, hoʻopaneʻe i ka hoʻokaʻawale ʻana o ka ʻōpū, a me ka hoʻonui ʻana i ka māʻona, hoʻohaʻahaʻa pono ia i nā pae hemoglobin A1c a hoʻemi i ke kaumaha o ka maʻi. Hoʻohui ʻia, hoʻomaikaʻi ka lāʻau lapaʻau i nā mea pilikia cardiovascular e like me ka pae lipid a me ke kahe koko a hōʻike i ka pono i ka steatohepatitis non-alcoholic.

No ka mea kakau

ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.

Mea kākau moʻolelo ʻepekema

Hoʻopili ʻia ʻo De Block C me ke Kulanui o Antwerp a me kāna mau ʻoihana pili i Belgium, me ka Inflamed Ctr Excellence, University Hospital Antwerp (UZA a me Univ Hosp Antwerp), a me ka Infla Med Ctr Excellence. ʻO kāna noiʻi ʻana e pili ana i nā ʻano aʻoaʻo, e like me Endocrinology & Metabolism, kahi e nānā ai ʻo ia i nā hormones a me nā maʻi metabolic; Gastroenterology & Hepatology, e ʻimi ana i nā maʻi ʻai a me nā ate; General & Internal Medicine, e kamaʻilio ana i ka hōʻailona a me ka mālama ʻana i nā maʻi maʻamau o loko; Nutrition & Dietetics, e noiʻi ana i ka meaʻai a me kona hopena olakino; a me Urology & Nephrology, ke aʻo ʻana i ka pathology a me ka hana lapaʻau o nā maʻi mimi a me nā maʻi maʻi. He haumana ʻo ia me nā haʻawina nui i nā ʻoihana lapaʻau he nui. Ua helu ʻia ʻo De Block C ma ka ʻōlelo kuhikuhi [4].

▎ Nā ʻōlelo pili

[1] Wong E, Cope R, Dima L, et al. ʻO Tirzepatid: He ʻelua Glucose-dependent Insulinotropic Polypeptide a me Glucagon-Like Peptide-1 Agonist no ka mālama ʻana i ke ʻano 2 Diabetes Mellitus [J]. American Journal of Therapeutics, 2023,30(1):e26-e35.DOI:10.1097/MJT.0000000000001588.

[2] Kumar D, Harshidha D, Mousigan M, et al. He Manaʻo ma luna o Tirzepatid, ʻelua-Targeted Lapaʻau no ka maʻi diabetes a me ka momona [J]. Ka Nupepa International of Innovative Research & Growth, 2022,7:983.DOI:10.5281/zenodo.7420605.

[3] Sweta, Gupta S, Bansal S, et al. ʻO Tirzepatid kahi mole anti diabetic hou e wehe i ka hana pālua [J]. E ʻike i ke olakino lehulehu, 2024,21(1):75.DOI:10.1186/s12982-024-00200-2.

[4] De Block C, Bailey C, Wysham C, et al. ʻO Tirzepatid no ka mālama ʻana i nā pākeke me ka maʻi diabetes type 2: He hiʻohiʻona endocrine [J]. Diabetes Obesity & Metabolism, 2023,25(1):3-17.DOI:10.1111/dom.14831.

[5] Sood A, Kaur P, Syed O, et al. Hoʻololi i ka mālama maʻi diabetes: wehe i ka hiki o Tirzepatid i ka mana glycemic a ma waho aʻe [J]. Ka Manaʻo Manaʻo o Clinical Pharmacology, 2024,17(3):235-246.DOI:10.1080/17512433.2024.2310070.

[6] Grover-Páez F, Gómez A, Suárez A, et al. Mai kahi hoʻokokoke glycocentric i ka mea maʻi me ka maʻi diabetes mellitus type 2 a hiki i ka mālama ʻana i ka multi-organ prevention a me ka emi ʻana o nā hopena neuro-nephro-cardiovascular.[M]//2023.DOI: 10.5772/intechopen.1002363.

ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.  

ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a maʻi paha. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.